RxDoctor Payments Data

Kurtis Melin, MD

Family Medicine · Spartanburg, SCNPI 1467749929

Payments from drug & device makers

$3,437in general payments, 2019–2025

Across 51 payments — averaging $67.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$654
  • Neurocrine Biosciences, Inc.$458
  • Johnson & Johnson$392
  • Otsuka America Pharmaceutical, Inc.$315
  • Pfizer$307
  • Acadia Pharmaceuticals Inc$194
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,437100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,437 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$94,277
Medicare patients
372
Services billed
867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,183$234,770
Invega SustennaPaliperidone Palmitate32$66,192
NuedextaDextromethorphan Hbr/Quinidine120$58,850
RexultiBrexpiprazole41$53,357
XareltoRivaroxaban201$38,401
TrulicityDulaglutide42$38,005
FarxigaDapagliflozin Propanediol185$36,839
TradjentaLinagliptin215$34,967
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$33,849
XifaxanRifaximin42$33,785
Breo ElliptaFluticasone/Vilanterol67$25,758
AbrysvoRsv Vacc, Pref A And Pref B/Pf73$23,315
Divalproex Sodium1,221$19,336
OzempicSemaglutide19$19,229
JardianceEmpagliflozin109$17,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$307$258,0851,256 claims
Johnson & JohnsonInvega Sustenna, Xarelto$392$104,593233 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$92$72,071165 claims
Avanir Pharmaceuticals, Inc.Nuedexta$128$58,850120 claims
Otsuka America Pharmaceutical, Inc.Rexulti$315$53,35741 claims
AstraZenecaFarxiga, Brilinta$654$45,939250 claims
AbbVieCreon, Restasis, Vraylar, Linzess$101$38,83867 claims
Lilly USA, LLCTrulicity$18$38,00542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →